Optimal Duration of Antibiotic Therapy in Patients With Hematogenous Vertebral Osteomyelitis at Low Risk and High Risk of Recurrence (Q38751083)

6 September 2017

title

Optimal Duration of Antibiotic Therapy in Patients With Hematogenous Vertebral Osteomyelitis at Low Risk and High Risk of Recurrence (English)

1 reference

6 September 2017

1 reference

1 reference

6 September 2017

Ki-Ho Park

1 reference

6 September 2017

Oh-Hyun Cho

1 reference

6 September 2017

Jung Hee Lee

1 reference

6 September 2017

Ji Seon Park

1 reference

6 September 2017

Kyung Nam Ryu

1 reference

6 September 2017

Seong Yeon Park

1 reference

6 September 2017

Yu-Mi Lee

1 reference

6 September 2017

Yong Pil Chong

1 reference

6 September 2017

Sung-Han Kim

1 reference

6 September 2017

Sang-Oh Lee

1 reference

6 September 2017

In-Gyu Bae

1 reference

6 September 2017

Yang Soo Kim

1 reference

6 September 2017

Jun Hee Woo

1 reference

6 September 2017

Mi Suk Lee

1 reference

6 September 2017

language of work or name

English

0 references

publication date

24 February 2016

1 reference

Clinical Infectious Diseases

6 September 2017

published in

1 reference

6 September 2017

1 reference

6 September 2017

1 reference

6 September 2017

page(s)

1262-1269

1 reference

Spondylodiscitis: update on diagnosis and management

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Infectious spondylodiscitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Changing trends in the epidemiology of pyogenic vertebral osteomyelitis: the impact of cases with no microbiologic diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Streptococcal vertebral osteomyelitis: multiple faces of the same disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Health care associated hematogenous pyogenic vertebral osteomyelitis: a severe and potentially preventable infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Pyogenic vertebral osteomyelitis: a systematic review of clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Vertebral osteomyelitis: long-term outcome for 253 patients from 7 Cleveland-area hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Hematogenous vertebral osteomyelitis due to Staphylococcus aureus in the adult: clinical features and therapeutic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Clinical characteristics and therapeutic outcomes of hematogenous vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Clinical characteristics and outcomes of hematogenous vertebral osteomyelitis caused by gram-negative bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Therapeutic outcomes of hematogenous vertebral osteomyelitis with instrumented surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Shorter treatments for vertebral osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Factors associated with treatment failure in vertebral osteomyelitis requiring spinal instrumentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Comparison of clinical features and outcomes of staphylococcus aureus vertebral osteomyelitis caused by methicillin-resistant and methicillin-sensitive strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Therapeutic outcomes of pyogenic vertebral osteomyelitis requiring spinal instrumentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Risk factors and treatment outcomes in osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Antibiotic treatment of gram-positive bone and joint infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Safety of instrumentation in patients with spinal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Clinical practice. Vertebral osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

Optimal Duration of Antibiotic Therapy in Vertebral Osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW098

21 January 2018

Identifiers

DOI

10.1093/CID/CIW098

1 reference

6 September 2017

1 reference